Because of a lapse in government funding, the information on this
website may not be up to date, transactions submitted via the
website may not be processed, and the agency may not be able to
respond to inquiries until appropriations are enacted. The NIH
Clinical Center (the research hospital of NIH) is open. For more
details about its operating status, please visit
cc.nih.gov. Updates
regarding government operating status and resumption of normal
operations can be found at
opm.gov.
Brimonidine Tartrate, Timolol Maleate Drug Combination MeSH Descriptor Data 2026
A pharmaceutical preparation of brimonidine tartrate and timolol maleate. The combined ADRENERGIC ALPHA2 RECEPTOR AGONIST and ADRENERGIC BETA-ANTAGONIST activity of these drugs reduce INTRAOCULAR PRESSURE in GLAUCOMA patients.
Entry Term(s)
Brimonidine Tartrate-Timolol Maleate
Brimonidine Tartrate-Timolol Maleate Drug Combination
2016; BRIMONIDINE TARTRATE-TIMOLOL MALEATE DRUG COMBINATION was indexed under QUINOXALINES 2011-2015, under TIMOLOL 2011-2015, and under DRUG COMBINATIONS 2011-2015
A pharmaceutical preparation of brimonidine tartrate and timolol maleate. The combined ADRENERGIC ALPHA2 RECEPTOR AGONIST and ADRENERGIC BETA-ANTAGONIST activity of these drugs reduce INTRAOCULAR PRESSURE in GLAUCOMA patients.